Teleconference: Wet AMD Therapies - Lucentis Add-on and Replacement (10:00 AM EST)

Time & Location

Originally Presented: November 15, 2012 10:00 AM, Teleconference


GLG Expert Contributors


    Please note the time listed above is in EST. For European clients, this call will take place at 15:00 GMT. While Lucentis has been cannibalized by the off-label use of Avastin and taken a cut in price by the more recently approved Eylea, Fovista may prove to be a useful add-on. Combination therapy appears to be more effective than Lucentis alone. Meanwhile, Allergan and Molecular Partners are hoping to compete with Lucentis (and Avastin) more directly with DARPin (Designed Ankyrin Repeat Protein) therapies, whose long half-life and high potency may reduce injection frequency. Please join Dr. W. Lloyd Clark, Clinical Assistant Professor of Ophthalmology, at the University of South Carolina School of Medicine, and Dr. Sebastian Wolf, Director of the Department of Ophthalmology at the Inselspital University of Bern, as they share their insight on:
  • Ophthotech's Fovista Anti-PDGF Therapy
  • Impact of emerging therapies on approved/currently available therapies for wet AMD
  • Potential DARPin platforms

View Webcasts & Teleconferences in Healthcare

View All Webcasts & Teleconferences in Healthcare

About GLG Live Meetings

A program focused on educating business and investment professionals through seminars on current trends and core concepts in various industries. Detailed workbooks distributed at the Seminars provide educational reference materials for later review. GLG Live Meetings enable clients to increase thier own industry education by proposing new seminar topics or adding agenda terms to currently scheduled seminars.